Product Description: Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12./[2]Reozalimab. IMGT/mAb-DB.